This study introduces a novel probiotic agent with significant anti-allergic properties. The agent comprises two strains: Bifidobacterium animalis subsp. lactis BLa36 and Lacticaseibacillus casei LC89.

This study presents the discovery and application of Lacticaseibacillus rhamnosus LRa66, a novel probiotic strain exhibiting significant capabilities of blood glucose and lipid reduction. Isolated from human breast milk, LRa66 demonstrates superior tolerance to gastric acid, intestinal fluid, and bile salts.

The study investigates the properties and applications of a novel strain of Lacticaseibacillus casei LC15 with significant immune-modulating and antimicrobial activities.

The present study introduces a composite probiotic blend comprising Bifidobacterium animalis subsp. lactis BLa36 and Bifidobacterium breve BBr60. This blend demonstrates synergistic effects in stabilizing mood by balancing neurotransmitters, reducing stress responses, and improving behavioral symptoms.

A newly discovered strain of Lactiplantibacillus plantarum Lp18 (CCTCC No: M 20231524), demonstrates significant potential in alleviating constipation and regulating the gut microbiota. This strain exhibits excellent survival in acidic and bile environments, broad-spectrum antibacterial properties, and significant efficacy in enhancing bowel movements.

The development of effective probiotics to enhance immune function is an area of growing interest in both scientific research and practical application. This journal entry details the innovative approach taken to create a composite probiotic product aimed at improving immune responses.